Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 107

recruiting
3 987
countries
28
conditions
2 109

1 824 trials match your criteria

Study on Basimglurant for Children, Adolescents, and Young Adults with Tuberous Sclerosis Complex-Related Seizures

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Basimglurant

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant

Study on the Effects of Satralizumab in Children and Adolescents with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002

Study of Trientine Dihydrochloride (Cufence) to Evaluate Its Effects and Safety in Patients with Wilson's Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Trientine Dihydrochloride

Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt

Colitis ulcerative

Not recruiting

Study on Vedolizumab for Patients with Active Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab

Hodgkin's disease+1

Not recruiting

Study of Pembrolizumab with Hyaluronidase for Patients with Relapsed or Refractory Hodgkin Lymphoma or Primary Mediastinal Large B-cell Lymphoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study on Long-Term Safety of INBRX-101 for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Human ALPHA-1-PROTEINASE inhibitor immunoglobulin G fusion protein, recombinant
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.